Structure via PubChem · Public domain (PubChem)
carfilzomib
Sign in to saveAlso known as Kyprolis®, PR-171
Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. It was developed by Onyx Pharmaceuticals.
Chemical data
- Formula
- C40H57N5O7
- Molecular weight
- 719.9 g/mol
- IUPAC name
- (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
- SMILES
- CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
- InChIKey
- BLMPQMFVWMYDKT-NZTKNTHTSA-N
- XLogP
- 4.7
- Polar surface area
- 158 Ų
- H-bond donors
- 4
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2009
- Admin. routes
- parenteral
- Indications
- acute lymphoblastic leukemia, multiple myeloma, leukemia, lymphoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 719.425799
- Has use
- medication
Show 5 more facts
- chemical formula
- C₄₀H₅₇N₅O₇
- isomeric SMILES
- CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
- canonical SMILES
- CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
- World Health Organisation international non-proprietary name
- carfilzomib
- Commons category
- Carfilzomib
via Wikidata · CC0
~6 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Mechanism
- History
- Clinical trials & side effects
- Completed
- ASPIRE trial
- Society and culture
- Economics
- References
Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. It was developed by Onyx Pharmaceuticals.
The US Food and Drug Administration (FDA) approved it in July 2012.
Excerpted from Wikipedia’s “carfilzomib” article, available under the CC BY-SA 4.0 licence.